Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 ...
Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.
LAS VEGAS , NV, UNITED STATES, January 27, 2025 /EINPresswire / -- DelveInsight's“Cold Agglutinin disease Market Insight, Epidemiology And Market Forecast - 2034′′ report offers an in-depth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback